New cell therapy targets EBV-Linked cancers in early trial
NCT ID NCT07450391
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase study is testing an experimental cell therapy called EBV-AST for people with Epstein-Barr virus (EBV)-related lymphoproliferative disorders, including certain blood cancers and post-transplant complications. About 18 adults will receive up to 3 infusions of the treatment to check safety and find the best dose. The goal is to see if the therapy can shrink tumors and control the disease, but it is not expected to be a cure.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EBV-ASSOCIATED POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Chinese PLA General Hospital
RECRUITINGBeijing, Beijing Municipality, 100853, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New vaccine aims to fight Hard-to-Treat EBV cancers
- New hope for hard-to-treat lymphoma: three-drug combo enters early trials
- New antibody shows promise against Post-Transplant virus threat
- Engineered immune cells take aim at stubborn lymphoma
- Supercharged t cells take on Hard-to-Treat lymphoma
- New drug cocktail targets Virus-Linked cancers in early trial